Get to know our clinical trials
Clinical trial of GEN1046 and antineoplastic treatment in subjects with non-small cell lung carcinoma
IN THIS TRIAL WE WANT TO FIND OUT HOW THE TRIAL DRUGS WORK AGAINST NSCLC AND TO LEARN ABOUT THE POSSIBLE SIDE EFFECTS OF THE TRIAL DRUG FOR TREATING NSCLC, BOTH IN MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB. THE RESULTS OF THIS TRIAL MAY BE USED FOR FURTHER DEVELOPMENT OF GEN1046. THEY MAY ALSO BE USED TO SEEK APPROVAL OF THE TRIAL DRUG TO TREAT CANCER.
Technical Summary
- PHASE II, MULTICENTER, RANDOMIZED, UNBLINDED, MULTICENTER TRIAL OF GEN1046 IN MONOTHERAPY AND IN COMBINATION WITH ANTINEOPLASTIC THERAPY IN SUBJECTS WITH METASTATIC, RECURRENT, OR REFRACTORY NON-SMALL CELL LUNG CARCINOMA AFTER BASELINE TREATMENT WITH AN IMMUNE CHECKPOINT INHIBITOR
- Code EudraCT: 2021-001928-17
- Protocol number: GCT1046-04
- Promoter: Genmab A/S
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.